DK0768084T3 - Kræftmetastaseinhibitor - Google Patents

Kræftmetastaseinhibitor

Info

Publication number
DK0768084T3
DK0768084T3 DK96909329T DK96909329T DK0768084T3 DK 0768084 T3 DK0768084 T3 DK 0768084T3 DK 96909329 T DK96909329 T DK 96909329T DK 96909329 T DK96909329 T DK 96909329T DK 0768084 T3 DK0768084 T3 DK 0768084T3
Authority
DK
Denmark
Prior art keywords
benzoic acid
cancerous metastasis
metastasis inhibitor
coch
conh
Prior art date
Application number
DK96909329T
Other languages
Danish (da)
English (en)
Inventor
Jiro Shibata
Konstanty Wierzba
Yuji Yamada
Koichi Shudo
Koji Murakami
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0768084T3 publication Critical patent/DK0768084T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96909329T 1995-04-10 1996-04-10 Kræftmetastaseinhibitor DK0768084T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8380395 1995-04-10
PCT/JP1996/000980 WO1996032101A1 (en) 1995-04-10 1996-04-10 Cancerous metastasis inhibitor

Publications (1)

Publication Number Publication Date
DK0768084T3 true DK0768084T3 (da) 2002-10-14

Family

ID=13812829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909329T DK0768084T3 (da) 1995-04-10 1996-04-10 Kræftmetastaseinhibitor

Country Status (12)

Country Link
US (1) US5750515A (de)
EP (1) EP0768084B1 (de)
JP (1) JP3208437B2 (de)
KR (1) KR100207356B1 (de)
AT (1) ATE223713T1 (de)
AU (1) AU693682B2 (de)
CA (1) CA2191850C (de)
DE (1) DE69623555T2 (de)
DK (1) DK0768084T3 (de)
ES (1) ES2180751T3 (de)
PT (1) PT768084E (de)
WO (1) WO1996032101A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-{〔1-(1,3-벤조디옥솔-5-일메틸-1h-이미다졸-5-일〕메틸}-4-(1-나프틸)-1h-피롤-3-일〕(4-메틸-1-피페라지닐)메타논의 약학적 조성물
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
SI1324970T1 (sl) 2000-10-02 2009-02-28 Hoffmann La Roche Retinoidi za zdravljenje emfizema
US8198328B2 (en) 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
AU2006221479B2 (en) * 2005-03-08 2011-04-21 Taiho Pharmaceutical Co., Ltd. Method of treating liver cancer
KR20080072823A (ko) * 2005-10-24 2008-08-07 다이호야쿠힌고교 가부시키가이샤 RAR-α 작동제의 유효성의 예측방법
TW200922554A (en) * 2007-10-11 2009-06-01 Taiho Pharmaceutical Co Ltd Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513238A (en) * 1978-07-17 1980-01-30 Banyu Pharmaceut Co Ltd Novel compound having immunoactivating action, its preparation and application
JP2752630B2 (ja) * 1988-03-29 1998-05-18 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
JP2761023B2 (ja) * 1989-03-20 1998-06-04 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
JPH0366647A (ja) * 1989-08-03 1991-03-22 Koichi Shudo フェニルベンゾエート誘導体
JPH03115289A (ja) * 1989-09-28 1991-05-16 Koichi Shudo 新規安息香酸誘導体、その製造方法及びその用途
JP3650144B2 (ja) * 1994-06-08 2005-05-18 花王株式会社 細胞接着抑制剤

Also Published As

Publication number Publication date
US5750515A (en) 1998-05-12
KR100207356B1 (ko) 1999-07-15
DE69623555D1 (de) 2002-10-17
EP0768084A4 (de) 1999-05-06
ATE223713T1 (de) 2002-09-15
CA2191850C (en) 2002-06-18
JP3208437B2 (ja) 2001-09-10
CA2191850A1 (en) 1996-10-17
WO1996032101A1 (en) 1996-10-17
EP0768084A1 (de) 1997-04-16
ES2180751T3 (es) 2003-02-16
AU5287596A (en) 1996-10-30
KR970703761A (ko) 1997-08-09
DE69623555T2 (de) 2003-05-15
AU693682B2 (en) 1998-07-02
PT768084E (pt) 2002-12-31
EP0768084B1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
FI970246A7 (fi) Dihydrobentsofuraanit
DK0941218T3 (da) Antithrombotiske organiske nitrater
NO970495L (no) Aryltioforbindelser som anti-bakterielle og antivirale midler
DK0768084T3 (da) Kræftmetastaseinhibitor
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
NO20092832L (no) Fremgangsmate for karbonylering av en forbindelse
AU591860B2 (en) Pyrolidineamide derivative having anti-prolyl endopeptidase
DE69126460D1 (de) Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
DE3677471D1 (de) Pyrrolidinylamidesterderivate mit antiprolylendopeptidaseaktivitaet, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen.
YU47298B (sh) Derivati 16-dehidro-vitamina d3
ATE248156T1 (de) Verwendung von 7-acyltaxolen zur behandlung von multidrugresistenten zellen
SE0004101D0 (sv) New use
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AU6306190A (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
ID22762A (id) Komposisi untuk mengobati atau mencegah kanker prostat
SE9802546D0 (sv) Medicinal product and method for treatment and prevention of dyskinesia
ES2177623T3 (es) Composiciones farmaceuticas que contienen ceftriaxona y penems.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
TR200000753T2 (tr) Mukabil antifungal ajan için prodrog olarak tetrahidrofuran fosfat ve hidroksi esterleri.
KR970702869A (ko) 항종양성 인돌로피롤로카르바졸 유도체(antitumor indolopyprolocarbazole derivative)
DK0619817T3 (da) Hidtil ukendte farmaceutisk aktive flaviliumforbindelser
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
TH9340A (th) อนุพันธ์ของวิตามินอี ชนิดใหม่ของกรรมวิธีสำหรับการผลิตสารนั้น